Medical Care Costs Associated With Cancer in Integrated Delivery Systems
Search for other papers by Matthew P. Banegas in
Current site
Google Scholar
PubMed
Search for other papers by K. Robin Yabroff in
Current site
Google Scholar
PubMed
Search for other papers by Maureen C. O'Keeffe-Rosetti in
Current site
Google Scholar
PubMed
Search for other papers by Debra P. Ritzwoller in
Current site
Google Scholar
PubMed
Search for other papers by Paul A. Fishman in
Current site
Google Scholar
PubMed
Search for other papers by Ramzi G. Salloum in
Current site
Google Scholar
PubMed
Search for other papers by Jennifer Elston Lafata in
Current site
Google Scholar
PubMed
Search for other papers by Mark C. Hornbrook in
Current site
Google Scholar
PubMed
Background: The high economic burden of cancer is projected to continue growing. Cost-of-care estimates are key inputs for comparative effectiveness and economic analyses that aim to inform policies associated with cancer care. Existing estimates are based largely on SEER-Medicare data in the elderly, leaving a knowledge gap regarding costs for patients aged <65 years. Methods: We estimated total and net medical care costs using data on individuals diagnosed with breast, colorectal, lung, or prostate cancer (n=45,522) and noncancer controls (n=314,887) enrolled in 1 of 4 participating health plans. Net costs were defined as the difference in mean total costs between patients with cancer and controls. The phase-of-care approach and Kaplan-Meier Sample Average method were used to estimate mean total and net 1- and 5-year costs (in 2015 US dollars) by cancer site, stage at diagnosis, and age group (<65 and ≥65 years). Results: Total and net costs were consistently highest for lung cancer and lowest for prostate cancer. Net costs were higher across all cancer sites for patients aged <65 years than those aged ≥65 years. Medical care costs for all cancers increased with advanced stage at diagnosis. Conclusions: This study improves understanding of medical care costs for the 4 most common invasive cancers in the United States. Higher costs among patients aged <65 years highlight limitations of relying on SEER-Medicare data alone to understand the national burden of cancer, whereas higher costs for patients with advanced-stage cancer underscore the importance of early detection to curtail high long-term costs. These cost estimates can be used in the development and evaluation of interventions and policies across the cancer care continuum.
Author contributions: Study concept and design: Banegas, Yabroff, Hornbrook. Data analysis: Banegas, O'Keeffe-Rosetti. Interpretation of results: All authors. Manuscript preparation: All authors.
Supplementary Materials
- Supplemental Material (PDF 369 KB)
© 2019-2024 National Comprehensive Cancer Network